ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Código de la empresaNDRA
Nombre de la empresaENDRA Life Sciences Inc
Fecha de salida a bolsaJun 28, 2017
Fundada en2007
Director ejecutivoMr. Alexander Y. Tokman
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección3600 Green Ct Ste 350
CiudadANN ARBOR
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal48105-2440
Teléfono17343350468
Sitio Webhttps://www.endrainc.com/
Código de la empresaNDRA
Fecha de salida a bolsaJun 28, 2017
Fundada en2007
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos